This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Genethon, International Centre for Genetic Engineering and Biotechnology. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 59 
1 out of 6 Years Active: 2019
Title: Giulia Bortolussi: Innovator in Genetic Engineering
Introduction
Giulia Bortolussi is a prominent inventor based in Travesio, Italy. She has made significant contributions to the field of genetic engineering, particularly in the treatment of hyperbilirubinemia. Her innovative work has the potential to impact the lives of many individuals suffering from this condition.
Latest Patents
Giulia Bortolussi holds a patent for the treatment of hyperbilirubinemia. This invention relates to a nucleic acid sequence that is particularly useful in treating Crigler-Najjar syndrome. The nucleic acid sequence is a codon-optimized UGT1A1 coding sequence, which enhances the effectiveness of the treatment.
Career Highlights
Throughout her career, Giulia has worked with notable organizations such as Genethon and the International Centre for Genetic Engineering and Biotechnology. Her experience in these institutions has allowed her to develop her expertise in genetic therapies and innovations.
Collaborations
Giulia has collaborated with esteemed colleagues, including Federico Mingozzi and Giuseppe Ronzitti. These partnerships have further enriched her research and development efforts in the field of genetic engineering.
Conclusion
Giulia Bortolussi is a trailblazer in the realm of genetic engineering, with her innovative patent addressing a critical health issue. Her work exemplifies the impact that dedicated inventors can have on medical science and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile